ChemoCentryx Reports Third Quarter 2018 Financial Results and Recent Highlights 


$186 million in cash and investments at September 30, 2018

Received Orphan Drug Designation for CCX140 in Focal Segmental Glomerulosclerosis (FSGS)

We embark now upon exciting times. Looking forward to the coming year, we have set the stage for a sequence of key top-line data readouts from Schall, Ph. D., President and Chief Executive Officer of ChemoCentryx. We completed enrollment of our landmark ADVOCATE Phase III pivotal trial in ANCA-associated vasculitis in the third quarter, and plan to report top-line data in the fourth quarter of this coming year. We have clinical trials of avacopan in C3G and another unique asset, CCX140 in FSGS underway, and we stand on the brink of launching our definitive clinical trial of avacopan in Hidradenitis Suppurativa, our first foray into orphan dermatological disease. Our momentum grows ever stronger, enabled by a robust …

[Read on via official release]

Source: US SEC
View full document: